Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Corvus Pharmaceuticals (NASDAQ: CRVS) announced that its leadership team will hold one-on-one investor meetings and deliver a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) announced that its leadership team will hold one-on-one investor meetings and deliver a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston.
The fireside chat is scheduled for Monday, November 10, 2025 at 8:30 AM ET. A live webcast will be available and archived for 90 days via the company’s investor relations website.
Details
News Market Reaction – CRVS
On Oct 31, the day this news came out, CRVS closed 3.61% above the previous close.
Data tracked by StockTitan Argus for the Oct 31 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET.
A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.